In our study, we similarly demonstrated that the TB-1 peptide reduced liver inflammation in MASLD, as indicated by decreased expression of Il-1β and Tnf-α genes in liver tissue (Figure S4). This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.